CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肠道微生物组与肿瘤免疫治疗
英文原题：Gut microbiome and tumor immunotherapy.
查看英文原题
Gut microbiome and tumor immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多种创新分子技术已建立起肠道微生物组与癌症之间令人信服的联系。研究还揭示，微生物组及微生物组特异性代谢物可显著影响化疗、放疗和免疫治疗等癌症治疗。靶向免疫系统方法推动的癌症免疫治疗进展已大幅改善癌症治疗格局。然而，肿瘤免疫治疗的全部潜力仍有待探索，许多挑战仍需解决。本综述总结了当前关于微生物群存在的证据，以及其如何影响对FDA批准的癌症免疫疗法（如免疫检查点抑制剂（ICIs）或CAR-T（CAR-T）细胞疗法）的应答。此外，还讨论了肠道微生物组与癌症免疫治疗的挑战和局限性。
展开英文摘要原文
Multiple innovative molecular techniques have established compelling connections between the gut microbiome and cancers. Studies have also revealed that the microbiome and microbiome-specific metabolites can significantly influence cancer treatments like chemotherapy, radiotherapy, and immunotherapy. Advancements in cancer immunotherapy driven by a targeted immune system approach have considerably improved the treatment landscape in cancer.
However, the full potential of tumor immunotherapy remains to be explored, and many challenges need to be addressed. This review provides a summary of the current evidence regarding the presence of microbiota and how it can impact the response to Food and Drug Administration (FDA) approved cancer immunotherapies, such as immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T (CAR-T) cell therapy.
Additionally, it addresses the challenges and limitations of gut microbiome and cancer immunotherapy.
论文信息
- 作者
- Vig M、Dubey S
- 第一作者单位
- Amity Institute of Virology & Immunology, Amity University Uttar Pradesh (AUUP), Sector 125, Noida, Uttar Pradesh, India.India
- 通讯作者单位
- Amity Institute of Virology & Immunology, Amity University Uttar Pradesh (AUUP), Sector 125, Noida, Uttar Pradesh, India. Electronic address: sdubey@amity.edu.India
- 文献类型
- 综述
- 期刊
- International review of cell and molecular biology2025
- 原文标识
- PubMed 40623765 · DOI 10.1016/bs.ircmb.2024.12.014